John J Orloff's Net Worth
$4.89 Million
Who is John J Orloff?
John J Orloff has an estimated net worth of $4.89 Million. This is based on reported shares across multiple companies, which include QLT INC/BC, Baxalta Inc, ALEXION PHARMACEUTICALS INC, and Aegerion Pharmaceuticals, Inc..
SEC CIK
John J Orloff's CIK is 0001643941
Past Insider Trading and Trends
2015 was John J Orloff's most active year for acquiring shares with 4 total transactions. John J Orloff's most active month to acquire stocks was the month of June. 2016 was John J Orloff's most active year for disposing of shares, totalling 5 transactions. John J Orloff's most active month to dispose stocks was the month of May. 2020 saw John J Orloff paying a total of $3,741.20 for 51,597 shares, this is the most they've acquired in one year. In 2020 John J Orloff cashed out on 25,575 shares for a total of $3,825,022.28, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
NOVELION THERAPEUTICS INC. No price found
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Baxalta Inc No price found
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -96.38K |
—
|
—
|
0
|
Jun 3
| |||
Form 4
| +131.54% | 54.54K |
$39.30 | -$55,334.40 | 96.01K |
Mar 3
| |||
Form 4
|
∞
| 40.52K |
—
|
—
| 40.52K |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ALEXION PHARMACEUTICALS, INC. No price found
EVP, Research & Development
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -146.51K |
—
|
—
|
0
|
Jul 21
| |||
Form 4
| +69.64% | 60.14K |
—
|
—
| 146.51K |
Jul 14
| |||
Form 4
| -2.22% | -1.96K |
$177.00 | -$346,389.00 | 86.37K |
Jun 8
| |||
Form 4
| +38.33% | 24.47K |
—
|
—
| 88.32K |
Feb 28
| |||
Form 4
| +43.39% | 19.32K |
$125.75 | -$3,375,813.00 | 63.85K |
Dec 15 - Dec 16
| |||
Form 4
| -5.88% | -2.78K |
$114.61 | -$319,074.24 | 44.53K |
Jun 8
| |||
Form 4
| +25.20% | 9.52K |
$92.20 | -$122,827.16 | 47.31K |
Dec 15 - Mar 2
| |||
Form 4
| -6.87% | -2.79K |
$118.61 | -$330,447.46 | 37.79K |
Jun 7
| |||
Form 4
| +30.27% | 9.43K |
—
|
—
| 40.58K |
Feb 28
| |||
Form 4
| -2.02% | -641.00 |
$112.97 | -$86,558.66 | 31.15K |
Dec 15 - Feb 28
| |||
Form 4
| -6.24% | -2.12K |
$118.53 | -$250,690.95 | 31.79K |
Jun 8
| |||
Form 4
| +35.81% | 8.94K |
—
|
—
| 33.91K |
Feb 28
| |||
Form 4
|
∞
| 24.96K |
—
|
—
| 24.96K |
Jun 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aegerion Pharmaceuticals, Inc. No price found
EVP, Research and Development
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Zenas BioPharma, Inc. (ZBIO) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||